Vor Biopharma Inc. (NYSE:VOR) Given Average Rating of “Buy” by Brokerages

Vor Biopharma Inc. (NYSE:VOR) has been given an average rating of “Buy” by the seven brokerages that are covering the firm, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $8.86.

A number of research analysts recently commented on the company. HC Wainwright decreased their price objective on Vor Biopharma from $17.50 to $13.00 and set a “buy” rating on the stock in a report on Friday, March 21st. Oppenheimer reaffirmed an “outperform” rating and issued a $8.00 price target on shares of Vor Biopharma in a research note on Friday, March 21st. Wedbush reissued an “outperform” rating and set a $7.00 price objective on shares of Vor Biopharma in a research report on Thursday, March 20th. Stifel Nicolaus decreased their target price on shares of Vor Biopharma from $12.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. Finally, JMP Securities reiterated a “market outperform” rating and set a $12.00 price target on shares of Vor Biopharma in a research report on Tuesday, December 10th.

Hedge Funds Weigh In On Vor Biopharma

Hedge funds and other institutional investors have recently bought and sold shares of the company. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new stake in shares of Vor Biopharma during the fourth quarter worth about $33,000. Virtu Financial LLC acquired a new position in shares of Vor Biopharma during the fourth quarter worth about $60,000. XTX Topco Ltd purchased a new stake in shares of Vor Biopharma during the fourth quarter worth approximately $80,000. Trustees of Columbia University in the City of New York acquired a new stake in Vor Biopharma in the fourth quarter valued at approximately $102,000. Finally, Northern Trust Corp lifted its stake in Vor Biopharma by 39.0% in the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock worth $175,000 after acquiring an additional 44,252 shares during the last quarter. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

Vor Biopharma Price Performance

NYSE:VOR opened at $0.81 on Thursday. The company’s 50-day moving average is $1.19 and its two-hundred day moving average is $1.01. Vor Biopharma has a 1-year low of $0.63 and a 1-year high of $2.43. The firm has a market capitalization of $55.63 million, a price-to-earnings ratio of -0.49 and a beta of -0.40.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.